Exocrine pancreas cancer and thromboembolic events: A systematic literature review

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 10, Issue 7, 2012, Pages 835-846

  Epstein, Andrew S ^a   O'Reilly, Eileen M ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN III; ANTIVITAMIN K; BLOOD CLOTTING FACTOR 7A INHIBITOR; CAPECITABINE; CERTOPARIN; CISPLATIN; D DIMER; DALTEPARIN; DOCETAXEL; DOXORUBICIN; ENOXAPARIN; ERYTHROPOIETIN; FIBRIN; FLUOROURACIL; GEMCITABINE; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW MOLECULAR WEIGHT HEPARIN; MEGESTROL; NADROPARIN; PADGEM PROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBIN; THROMBOCYTE FACTOR 4; THROMBOMODULIN; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR; WARFARIN;

ADVANCED CANCER; ANEMIA; ANTICOAGULATION; ARTICLE; BLEEDING; BLOOD GROUP A; BODY WEIGHT; CANCER CHEMOTHERAPY; CANCER SURGERY; CARDIOVASCULAR RISK; CLINICAL FEATURE; COMORBIDITY; DIABETES MELLITUS; HEART DISEASE; HISTOPATHOLOGY; HUMAN; KIDNEY DISEASE; LEUKOCYTOSIS; LIVER DISEASE; LUNG EMBOLISM; MEDICAL EDUCATION; OUTCOME ASSESSMENT; PANCREAS CANCER; PRIMARY PREVENTION; SECONDARY PREVENTION; SEDENTARY LIFESTYLE; SINGLE BLIND PROCEDURE; SOLID TUMOR; SYSTEMATIC REVIEW; THROMBOCYTOSIS; THROMBOEMBOLISM; THROMBOGENICITY; THROMBOSIS; TREATMENT DURATION; VEIN CATHETERIZATION; VEIN THROMBOSIS;

EID: 84865322916     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2012.0087     Document Type: Article

References (87)

1. Blom JW, Osanto S, Rosendaal FR. High risk of venous thrombosis in patients with pancreatic cancer: a cohort study of 202 patients. Eur J Cancer 2006;42:410-414.
2. Cubilla A, Fitzgerald PJ. Pancreas cancer. I. Duct adenocarcinoma. A clinical-pathologic study of 380 patients. Pathol Annu 1978;13(Pt 1):241-289.
3. Mandala M, Reni M, Cascinu S, et al. Venous thromboembolism predicts poor prognosis in irresectable pancreatic cancer patients. Ann Oncol 2007;18:1660-1665.
4. Oh SY, Kim JH, Lee KW, et al. Venous thromboembolism in patients with pancreatic adenocarcinoma: lower incidence in Asian ethnicity. Thromb Res 2008;122:485-490.
5. Pinzon R, Drewinko B, Trujillo JM, et al. Pancreatic carcinoma and Trousseau's syndrome: experience at a large cancer center. J Clin Oncol 1986;4:509-514.
6. Mitry E, Taleb-Fayad R, Deschamps A, et al. Risk of venous thrombosis in patients with pancreatic adenocarcinoma. Gastroenterol Clin Biol 2007;31:1139-1142.
7. Sgouros J, Maraveyas A. Excess premature (3-month) mortality in advanced pancreatic cancer could be related to fatal vascular thromboembolic events. A hypothesis based on a systematic review of phase III chemotherapy studies in advanced pancreatic cancer. Acta Oncologica 2008;47:337-346.
8. Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000;343:1846-1850.
9. Mandala M, Labianca R, Agnelli G, et al. Multicenter, prospective, case-control, observational study on the influence of venous thromboembolism on patient outcome [abstract]. J Clin Oncol 2011;29(Suppl):Abstract 1554.
10. Piccioli A, Falanga A, Prandoni P. Anticoagulants and cancer survival. Semin Thromb Hemost 2006;32:810-813.
11. Zacharski LR, Lee AY. Heparin as an anticancer therapeutic. Expert Opin Investig Drugs 2008;17:1029-1037.
12. Trousseau A. Phlegmasia alba dolens. Clinique Medicale de l'Hotel-Dieu de Paris, 2nd ed. Paris, France: The Sydenham Society; 1865:654-712.
13. Ay C, Dunkler D, Marosi C, et al. Prediction of venous thromboembolism in cancer patients. Blood 2010;116:5377-5382.
14. Khorana AA, Kuderer NM, Culakova E, et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008;111:4902-4907.
15. Louzada L, Lazo-Langner A, Dao V, et al. Development of a clinical prediction rule for risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism [abstract]. Presented at the 53rd ASH Annual Meeting and Exposition; December 10-13, 2011; San Diego, California. Abstract 475.
16. Vemulapalli S, Chintala L, Tsimberidou AM, et al. Clinical outcomes and factors predicting development of venous thromboembolic complications in patients with advanced refractory cancer in a phase I clinic: the M. D. Anderson Cancer Center experience. Am J Hematol 2009;84:408-413.
17. Ay C, Dunkler D, Marosi C, et al. Prediction of venous thromboembolism in cancer patients. Blood 2010;116:5377-5382.
18. Khorana AA, Francis CW, Culakova E, et al. Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol 2006;24:484-490.
19. Simanek R, Vormittag R, Ay C, et al. High platelet count associated with venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). J Thromb Haemost 2010;8:114-120.
20. Li Z, Webb WB, Mao J, et al. Role of hypoalbuminemia in the development of venous thromboembolism in cancer chemotherapy patients [abstract]. J Clin Oncol 2011;29(Suppl):Abstract 9032.
21. Greenblatt DY, Wan Y, Winslo ER, et al. Body mass index is associated with morbidity after pancreatic resection: results from the ACS-NSQIP. Ann Surg Oncol 2011;18:S118.
22. Shukla A, Shukla S, Zhou X, et al. Association of ABO blood type A and stage IV disease with venous thromboembolism in pancreatic cancer patients [abstract]. J Clin Oncol 2010;28:Abstract e14529.
23. Ay C, Vormittag R, Dunkler D, et al. D-dimer and prothrombin fragment 1 + 2 predict venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study. J Clin Oncol 2009;27:4124-4129.
24. Ay C, Simanek R, Vormittag R, et al. High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). Blood 2008;112:2703-2708.
25. Ay C, Dunkler D, Simanek R, et al. Prediction of venous thromboembolism in patients with cancer by measuring thrombin generation: results from the Vienna Cancer and Thrombosis Study. J Clin Oncol 2011;29:2099-2103.
26. Cushman M. Epidemiology and risk factors for venous thrombosis. Semin Hematol 2007;44:62-69.
27. Khorana AA, Connolly GC. Assessing risk of venous thromboembolism in the patient with cancer. J Clin Oncol 2009;27:4839-4847.
28. Shivakumar SP, Anderson DR, Couban S. Catheter-associated thrombosis in patients with malignancy. J Clin Oncol 2009;27:4858-4864.
29. Bennett CL, Silver SM, Djulbegovic B, et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 2008;299:914-924.
30. Lippi G, Franchini M, Favaloro EJ. Thrombotic complications of erythropoiesis-stimulating agents. Semin Thromb Hemost 2010;36:537-549.
31. Bligh M, Sehdev S, Kuruvilla P. Venous thrombosis in the setting of metastatic pancreatic carcinoma. Pathophysiol Haemost Thromb 2010;37:A104.
32. Dasanu CA. Gemcitabine: vascular toxicity and prothrombotic potential. Expert Opin Drug Saf 2008;7:703-716.
33. Moore R, Adel N, Bhutani M, et al. Cisplatin-based chemotherapy is associated with an unacceptably high incidence of thromboembolic events: a large retrospective analysis [abstract]. Presented at the 51st ASH Annual Meeting and Exhibition; December 5-8, 2009; New Orleans, Louisianna. Abstract 456.
34. Lindahl AK, Boffa MC, Abildgaard U. Increased plasma thrombomodulin in cancer patients. Thromb Haemost 1993;69:112-114.
35. Heinmoller E, Schropp T, Kisker O, et al. Tumor cell-induced platelet aggregation in vitro by human pancreatic cancer cell lines. Scand J Gastroenterol 1995;30:1008-1016.
36. Haas SL, Jesnowski R, Steiner M, et al. Expression of tissue factor in pancreatic adenocarcinoma is associated with activation of coagulation. World J Gastroenterol 2006;12:4843-4849.
37. Andren-Sandberg A, Lecander I, Martinsson G, Astedt B. Peaks in plasma plasminogen activator inhibitor-1 concentration may explain thrombotic events in cases of pancreatic carcinoma. Cancer 1992;69:2884-2887.
38. Poruk KE, Firpo MA, Huerter LM, et al. Serum platelet factor 4 is an independent predictor of survival and venous thromboembolism in patients with pancreatic adenocarcinoma. Cancer Epidemiol Biomarkers Prev 2010;19:2605-2610.
39. Thomas GM, Panicot-Dubois L, Lacroix R, et al. Cancer cellderived microparticles bearing P-selectin glycoprotein ligand 1 accelerate thrombus formation in vivo. J Exp Med 2009;206:1913-1927.
40. Mirshahi S, Soria C, Chidiac J, et al. Plasma soluble fibrin level, a clinically useful predictor of thrombosis in cancer patients? J Thromb Haemost 2009;7:797-798.
41. Kurer MA. Protein and mRNA expression of tissue factor pathway inhibitor-1 (TFPI-1) in breast, pancreatic and colorectal cancer cells. Mol Biol Rep 2007;34:221-224.
42. Silberberg JM, Gordon S, Zucker S. Identification of tissue factor in two human pancreatic cancer cell lines. Cancer Res 1989;49:5443-5447.
43. Delluc A, Rousseau A, Delluc C, et al. Venous thromboembolism in patients with pancreatic cancer: implications of circulating tissue factor. Blood Coagul Fibrinolysis 2011;22:295-300.
44. Davila M, Amirkhosravi A, Coll E, et al. Tissue factor-bearing microparticles derived from tumor cells: impact on coagulation activation. J Thromb Haemost 2008;6:1517-1524.
45. Yates KR, Welsh J, Echrish HH, et al. Pancreatic cancer cell and microparticle procoagulant surface characterization: involvement of membrane-expressed tissue factor, phosphatidylserine and phosphatidylethanolamine. Blood Coagul Fibrinolysis 2011;22:680-687.
46. Zwicker JI, Liebman HA, Neuberg D, et al. Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy. Clin Cancer Res 2009;15:6830-6840.
47. Akl EA, van Doormaal FF, Barba M, et al. Parenteral anticoagulation may prolong the survival of patients with limited small cell lung cancer: a Cochrane systematic review. J Exp Clin Cancer Res 2008;27:4.
48. Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003;349:146-153.
49. Lee AY, Rickles FR, Julian JA, et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol 2005;23:2123-2129.
50. Siragusa S, Cosmi B, Piovella F, et al. Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis. Am J Med 1996;100:269-277.
51. Gould MK, Dembitzer AD, Doyle RL, et al. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials. Ann Intern Med 1999;130:800-809.
52. Hettiarachchi RJ, Smorenburg SM, Ginsberg J, et al. Do heparins do more than just treat thrombosis? The influence of heparins on cancer spread. Thromb Haemost 1999;82:947-952.
53. Dolovich LR, Ginsberg JS, Douketis JD, et al. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency. Arch Intern Med 2000;160:181-188.
54. Zacharski LR, Henderson WG, Rickles FR, et al. Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck, and prostate. Final report of VA Cooperative Study #75. Cancer 1984;53:2046-2052.
55. Chahinian AP, Propert KJ, Ware JH, et al. A randomized trial of anticoagulation with warfarin and of alternating chemotherapy in extensive small-cell lung cancer by the Cancer and Leukemia Group B. J Clin Oncol 1989;7:993-1002.
56. Lebeau B, Chastang C, Brechot JM, et al. Subcutaneous heparin treatment increases survival in small cell lung cancer. "Petites Cellules" Group. Cancer 1994;74:38-45.
57. Maurer LH, Herndon JE II, Hollis DR, et al. Randomized trial of chemotherapy and radiation therapy with or without warfarin for limited-stage small-cell lung cancer: a Cancer and Leukemia Group B study. J Clin Oncol 1997;15:3378-3387.
58. Altinbas M, Coskun HS, Er O, et al. A randomized clinical trial of combination chemotherapy with and without low-molecularweight heparin in small cell lung cancer. J Thromb Haemost 2004;2:1266-1271.
59. Kakkar AK, Levine MN, Kadziola Z, et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol 2004;22:1944-1948.
60. Klerk CP, Smorenburg SM, Otten HM, et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 2005;23:2130-2135.
61. Sideras K, Schaefer PL, Okuno SH, et al. Low-molecular-weight heparin in patients with advanced cancer: a phase 3 clinical trial. Mayo Clin Proc 2006;81:758-767.
62. Kuderer N, Ortel T, Khorana A, et al. Low molecular weight heparin thromboprophylaxis in ambulatory cancer patients: a systematic review and meta-analysis of randomized controlled trials [abstract]. Blood 2009;114:Abstract 490.
63. Kuderer NM, Khorana AA, Lyman GH, Francis CW. A metaanalysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment: impact on survival and bleeding complications. Cancer 2007;110:1149-1161.
64. Lazo-Langner A, Goss GD, Spaans JN, Rodger MA. The effect of low-molecular-weight heparin on cancer survival. A systematic review and meta-analysis of randomized trials. J Thromb Haemost 2007;5:729-737.
65. Khorana AA, Streiff MB, Farge D, et al. Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action. J Clin Oncol 2009;27:4919-4926.
66. Giever TA, Adwan KM, Cheng Y, Atallah EL. Comparison of venous thromboemboli (VTE) incidence in cancer patients who are on statin therapy versus those not on statin therapy [abstract]. J Clin Oncol 2010;28:Abstract 9033.
67. Khemasuwan D, DiVietro ML, Tangdhanakanond K, et al. Statins decrease the occurrence of venous thromboembolism in patients with cancer. Am J Med 2010;123:60-65.
68. Sproul E. Carcinoma and venous thrombosis: the frequency of association of carcinoma in the body and tail of the pancreas with multiple venous thrombosis. Am J Cancer 1938:566-585.
69. Ogren M, Bergqvist D, Wahlander K, et al. Trousseau's syndrome - what is the evidence? A population-based autopsy study. Thromb Haemost 2006;95:541-545.
70. Mikal S, Campbell AJ. Carcinoma of the pancreas. Diagnostic and operative criteria based on one hundred consecutive autopsies. Surgery 1950;28:963-969.
71. Thompson CM, Rodgers LR. Analysis of the autopsy records of 157 cases of carcinoma of the pancreas with particular reference to the incidence of thromboembolism. Am J Med Sci 1952;223:469-478.
72. Soederstroem J, Bjersing L. Prevalence of thrombi in carcinoma of the pancreas. Acta Pathol Microbiol Scand 1963;59:443-446.
73. Mao C, Domenico DR, Kim K, et al. Observations on the developmental patterns and the consequences of pancreatic exocrine adenocarcinoma. Findings of 154 autopsies. Arch Surg 1995;130:125-134.
74. Lowe WC, Palmer ED. Carcinoma of the pancreas. An analysis of 100 patients. Am J Gastroenterol 1967;47:412-420.
75. Epstein AS, Soff GA, Capanu M, et al. Analysis of incidence and clinical outcomes in patients with thromboembolic events and invasive exocrine pancreatic cancer. Cancer, in press.
76. Shaib W, Deng Y, Zilterman D, et al. Assessing risk and mortality of venous thromboembolism in pancreatic cancer patients. Anticancer Res 2010;30:4261-4264.
77. Maraveyas A, Waters J, Roy R, et al. Gemcitabine with or without prophylactic weight-adjusted dalteparin in patients with advanced or metastatic pancreatic cancer (APC): a multicentre, randomised phase IIB trial (the UK FRAGEM study)[abstract]. Eur J Cancer 2009;7:362:Abstract 6503.
78. Agnelli G, Gussoni G, Bianchini C, et al. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol 2009;10:943-949.
79. Riess H, Pelzer U, Opitz B, et al. A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy: final results of the CONKO-004 trial [abstract]. J Clin Oncol 2010;28(Suppl):Abstract 4033.
80. Icli F, Akbulut H, Utkan G, et al. Low molecular weight heparin (LMWH) increases the efficacy of cisplatinum plus gemcitabine combination in advanced pancreatic cancer. J Surg Oncol 2007;95:507-512.
81. von Delius S, Ayvaz M, Wagenpfeil S, et al. Effect of low-molecularweight heparin on survival in patients with advanced pancreatic adenocarcinoma. Thromb Haemost 2007;98:434-439.
82. van Doormaal FF, Di Nisio M, Otten HM, et al. Randomized trial of the effect of the low molecular weight heparin nadroparin on survival in patients with cancer. J Clin Oncol 2011;29:2071-2076.
83. Louzada ML, Majeed H, Wells PS. Efficacy of low- molecular-weight- heparin versus vitamin K antagonists for long term treatment of cancer-associated venous thromboembolism in adults: a systematic review of randomized controlled trials. Thromb Res 2009;123:837-844.
84. Price LH, Nguyen MB, Picozzi VJ, Kozarek RA. Portal vein thrombosis in pancreatic cancer: natural history, risk factors, and implications for patient management [abstract]. Presented at the 2010 Gastrointestinal Cancers Symposium; January 22-24, 2010; Orlando, Florida. Abstract 143.
85. Nakchbandi W, Müller H, Singer MV, et al. Prospective study on warfarin and regional chemotherapy in patients with pancreatic carcinoma. J Gastrointestin Liver Dis 2008;17:285-290.
86. Loprinzi CL, Kugler JW, Sloan JA, et al. Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia. J Clin Oncol 1999;17:3299-3306.
87. Streiff MB, Bockenstedt PL, Cataland SR, et al. NCCN Clinical Practice Guidelines in Oncology for Venous Thromboembolic Disease, version 2.2011. Available at: NCCN.org. Accessed April 18, 2012.